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Abstract – A characteristic tumor suppressor protein 53 (p53) mutational profile of genotoxic action of aristolochic acid 
was identified in the upper urothelial carcinoma (UUTT) associated with Balkan nephropathy (BEN). In the present study, 
we examined the prognostic value of tissue-based molecular markers in overall-survival (OS) risk after surgical treatment 
of UUTT, adjusted for gender, age and urological characteristics in 32 patients with BEN. Immunohistochemical exami-
nation of p53, the proliferation cell nuclear antigen (PCNA), the human epidermal growth factor receptor 2 (c-ErbB2; 
also known as HER-2/neu) proto-oncogene and the in situ terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay for apoptosis detection were used to examine serial tumor sections. The median OS-time was 60 months 
for UUTT operation; the mortality rate (18.7%) was related to (new) disease (re)occurrence or invasion in 12-216 months. 
High-grade (p=0.029), TUNEL>0.36%+ cells (p=0.010), and c-ErbB2+ cells (p=0.014) can define the risk of tumor inva-
sion. Patients with Balkan nephropathy that develop UUTT at a stage greater than pT1 (with apoptosis TUNEL+ cells 
>0.36% and p53+ cells greater than 10%) were at high risk of poor-OS after the tumor surgery (h(x)=6.35; p=0.045).
The obtained data present evidence for p53, cErbB2 and apoptosis deregulation, as a result of environmental toxin action. 
This is the first report of molecular biomarker linkage with OS for BEN-associated UUTT.
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INTRODUCTION
Upper urinary tract tumors (UUTT) associated with 
Balkan endemic nephropathy (BEN) appear with an 
incidence that is 30 times higher than in the gen-
eral population (Petronic, 2000) in several villages 
along the tributaries of large rivers in Serbia, Bos-
nia, Croatia, Romania and Bulgaria. These tumors 
occur considerably more frequently as synchronous 
or successive bilateral tumors, while an additional 
bladder carcinoma may also develop (Petronic et al., 
1991). A third of the patients suffer from both BEN 
and UUTT. Overt renal insufficiency is common. 
However,  according  to  literature  data,  the  UUTT 
observed in patients from BEN regions is not an ag-
gressive tumor. Not one author has reported on the 642 MARINA SAVIN ET AL.
lower survival of patients with UUTT from BEN re-
gions, although these patients experience increased 
risk burdens. These patients had equal or even great-
er survival than patients that develop UUTT outside 
the endemic areas (Jankovic et al., 1998; 2013). Pet-
ronic and Savin (2001) have suggested slow growth 
of the UUTT in BEN patients that were on hemodi-
alysis. A new or recurring urothelial carcinoma has 
been evidenced in 20% of patients after 5-12 years, 
indirectly implying considerable patient survival in 
BEN regions (Petronic et al., 1995, 1997). 
UUTT presents molecular deregulation of the cell 
cycle in a biologically aggressive neoplasm. Classical 
tumor grading by light microscopy characteristics is 
less efficient than by molecular markers. There is a 
strong evidence for aristolochic acid genotoxic action 
and UUTT development in BEN patients presenting 
a characteristic p53 mutational profile (Grollman et 
al., 2007; Jelacic et al., 2012). The aim of the present 
study was to evaluate the prognostic potential of p53, 
PCNA, c-ErbB2, and TUNEL data in patients under-
going surgical treatment of BEN-associated UUTT. 
We found that neither classical tumor marker grades 
for cell atypia and stage of local invasion, or a sin-
gle molecular marker such as p53 PCNA, cErbB2 
or TUNEL data cannot predict patient survival. The 
presence of c-ErbB2+ cells and increased apoptosis 
could define tumor invasiveness. A positive [stage>1; 
TUNEL+ cells >0.36%; p53+cells >10%] triple mark-
er points to poor OS, which is a verification of the 
mutual genotoxic and cytotoxic action of putative 
agent (aristolochic acid) in BEN regions.
MATERIALS AND METHODS
UUTT  developed  in  members  of  affected  families 
by BEN and/or UUTT in endemic villages in Ser-
bia, with no other risk factors of urothelial cancer, 
such as heavy smoking or frequent use of analgesics 
or NSAIDs, were recorded. Histological diagnosis of 
UUTT by light microscopy was used to confirm upper 
urothelial carcinoma grade (1-3) and pT stage (1-4) 
for local spreading (Mostofi et al., 1973; Sobin et al., 
2002), with simultaneous examination for character-
istic tubulointerstitial pictures of BEN (nephrectomy 
or kidney biopsy). The recurring or new urinary tract 
tumors and renal function were regularly monitored 
after the operation. Tissue-based molecular biomar-
kers of UUTT were analyzed without knowledge of 
the clinical information or pathological findings; se-
rial 4 micrometer-thick sections of tumor specimens 
were fixed in 3-4% formalin immediately after surgi-
cal procedure.
The TUNEL assay was performed using the in 
situ cell death detection POD kit (Boehringer Man-
heim, Germany) essentially as described previously. 
Slides were rinsed in distilled water, lightly counter-
stained with Mayer’s hematoxylin and mounted un-
der Dako Glicer gel mounting medium. 
Mouse  anti-human  1/100  MoAb  PC-10  (anti-
PCNA,  DAKO),  rabbit  polyclonal  anti-human  c-
cErB2  antibodies  (1/100)  (HER-2  Code  A  0485/
Dao) and mouse anti-human monoclonal antibody 
Pan p53 (Clone D07, Dako), and the avidin-biotin 
peroxidase method (LSAB-2 kit; DAKO) were used. 
A minimum of 1 000 cells was counted on each tu-
mor section at 400 x magnification. More cells were 
counted in areas of positive cell clusters to provide a 
sample representative of staining across the entirety 
of a tumor for the final calculation of the percentage 
of positive tumor cells for each biomarker.
Statistical  analysis  was  performed  using  SPSS 
18.0. Each biomarker score was classified as positive 
with regard to the number of positive cells, as fol-
lows: PCNA+ cells >9.7%, cErb-B2+ cells, apoptosis 
index >0.36% TUNEL+ cells and p53+ cells great-
er than 10%. These cut-off values for tumor grade 
and stage greater than pT1 were evaluated by ROC 
curves in the analysis of a total of 80 cases of UUTT 
with endemic Balkan nephropathy, as we previously 
described, Savin and Petronic (2002). The apoptosis 
index of 0.4% TUNEL+cells placed between thresh-
old values for grade 3 and pT3 progression was in-
cluded in the analysis. OS after a tumor operation 
was expressed as the mean and median time. The 
Cox regression model was applied to calculate risk 
factors for OS that included the biomarkers PCNA, 
p53, c-ErbB2 and TUNEL+, together with classical TUNEL, p53, Erbb2+ UroThELiaL TUmor 643
pathological tumor grade and stage, urological char-
acteristics, family history of BEN and UUTT, renal 
insufficiency, hemodialysis treatment, all adjusted to 
age and gender. Kaplan Meier analysis defined groups 
of patients with greater survival by investigated pa-
rameters (Log rank test; p<0.05). The biomarker af-
firmation for predictor of tumor grade or pT-stage 
progression was approved in a discriminate upon the 
multinomial regression analysis.
RESULTS
The investigation included 32 patients (20 males and 
12 females) aged 59.5±7.5 years with UUTT associ-
ated with BEN. The patients were inhabitants, most-
ly from birth, of established endemic villages in Ser-
bia (median time of admission = 57 years). Several 
family members were commonly affected by one or 
both diseases, accounting for 60% of the family bur-
den for BEN, and one third for urinary tract tumor 
(Table 1). UUTT was found either in the renal pelvis 
of 22 patients, or in the upper part of the ureter, as 
multiple tumors in 13 cases. Bilateral simultaneous 
tumors were diagnosed in 3 patients, while 4 suf-
fered from bilateral successive UUTT; urinary blad-
der carcinoma was observed in 6 patients (18.7%). 
The patients underwent surgical treatment: 23 un-
derwent total nephroureterectomy, and 9 patients 
underwent conservative kidney-ureteral operations 
at the Urology Clinic of Belgrade from 1977-1997. 
The patient OS median time of 60 months was cal-
culated for the observation period of 78+46 months 
after  surgery.  Six  out  of  32  patients  (18.7%)  suc-
cumbed to disease reoccurrence or invasiveness dur-
ing the follow-up period (1, 12, 14, 48, 132, 135 and 
216 months). The medical records confirmed severe 
sepsis  and  distant  metastases  in  one  patient  who 
died 12 months after the operation. After 5 years of 
follow-up, 10 patients with normal renal function 
censored the subsequent medical survey. Not one 
of the general characteristics or the listed urological 
parameters of tumor presentation and growth (Ta-
ble 1) directly affected the patient OS rate, except 
for a worse outcome for bilateral, and especially for 
successive bilateral tumors (F=11.55; p=0.0031; Fig. 
1). Patient OS did not significantly differ with the 
surgical option, whether a conservative approach or 
radical total nephroureterectomy were performed. 
Patients with a lethal outcome were mainly treated 
by the radical option. The majority of non-invasive 
tumors (60%) were grade 2; the median stage/grade 
ratio was 0.83. There was a direct relation between 
tumor grade of cell atypia and stage of local spread-
ing (r=0.48; p=0.005). The OS rate decreased with 
the grade of progression and was 100%, 89.5% and 
63.6% for grades 1, 2 and 3, respectively. However, 
the grade and stage may not account for the risk of 
poor outcome after the surgical treatment, as re-
vealed by OS Cox regression analysis. 
The analysis of tumor specimens obtained at the 
operation verified that one third of the patients (12/32; 
37.5%) developed p53+UUTT (>10% of p53+cells); 
51.6% of UUTT contained c-ErbB2+ cells; the dis-
tribution of PCNA+ >9.7% of tumor cells (16/32; 
50%) was linked with a high proliferation index and 
increased apoptosis, calculated as TUNEL+ >0.3% 
cells (16/32; 50%). These biomarkers may define the 
cut-off for grade 2 and stages >1, reported in our pre-
vious investigation of 80 UUTT from BEN regions 
(Savin  and  Petronic,  2002).  Molecular  marker  c-
ErbB2 overexpression was more frequently present in 
advanced grade 3 than intermediate grade 2 (0.90+-
0.48 vs. 0.33+-0.48; FcErbB2=11.33; p=0.002), together 
with  local  invasion  pT  stage  2.7+-1.3  vs.  1.6+-1.0 
(Fstage=8.42; p=0.001). Multinomial regression analy-
sis revealed that c-ErbB2+ was a factor of grade pro-
gression (p=0.007); c-ErbB2+ (p=0.014); apoptosis 
index (TUNEL>0.36% positive cells; p=0.010) and 
the high grade of cell atypia (p=0.029) were biomar-
kers of tumor local invasion by pT, stage>1. How-
ever,  none  of  the  single  tissue-based  biomarkers, 
PCNA+, c-ErbB2+, apoptosis index (TUNEL+) or 
p53+, can significantly predict OS after the surgery. 
To overcome the limitations of a single marker, the 
patients were subjected to selection for two positive 
biomarkers for OS that allows for the calculation of 
their mutual contribution to cancerogenesis and OS. 
We found that the combinations of c-ErbB2+, p53+ 
status or a high apoptosis index could reveal OS risk 
after tumor operation. PCNA+ did not provide any 
information about patient survival.644 MARINA SAVIN ET AL.
In double-positive markers containing c-ErbB2+, 
the mutated c-ErbB2 increases the prognostic prob-
ability  of  p53+  (F=12.85;  p=0.0050)  or  TUNEL+ 
(F=8.90; p=0.0307) for the risk of late and delayed 
OS for a new or recurring tumor according to the 
Kaplan Meier stratification (Figs. 2 and 3). The lat-
ter points to the importance of the association of 
apoptosis increase and tumor invasion for patient 
Table 1. Urological characteristics of UUTT and family history for BEN/UUTT
Clinical characteristics No %
U
U
T
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p
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n
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t
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n
abdominal pain no / yes  22 / 10 68.7 / 31.3
hematuria no / yes 4 / 28 12.5 / 87.5
pyuria no / yes 24 / 8 75 / 25
localization
pyelum
urethra 
22
10
68.75
31.25
growth
solitary
multiply
19
13
59.37
40.63
*bilateral
unilateral
simultaneous
*successive
25
3
4
78.13
9.37
12.5
light 
microscopy
grade 1-3 2 / 19 / 11 6.3 / 59.4 / 34.4
pT-stage 1-4 17 / 3/ 6 / 6 53.1 / 9.4 / 18.8/ 18.8
b
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d
d
e
r
 
t
u
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r
at time of UUTT diagnosis
no tumor
before
concomitant
after
23
6
2
1
71.9
18.7
6.3
3.1
r
e
n
a
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i
n
s
u
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c
i
e
n
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y
at presentation 
none
mild
overt
ESRD - HD dependent
16
6
5
5
50.0
18.8
15.6
15.6
the kidney with UUTT
functional
declined function
non-functional
16
4
12
50.0
12.5
37.5
BEN at UUTT operation no / yes 0 / 32
HD at presentation no / yes 27 / 5 84.4 / 15.6
HD after the surgery no / yes 19 / 13 59.3 / 40.7
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BEN  no / yes 13 /19 40.7 / 59.3
UUTT no / yes 20 / 12 62.5 / 37.5
co-morbidity 
(excluding BEN) 
No
KVS
DT- ulcer operation
severe infection (sepsis)
other
13
7
5 
4 (1)
2
40.6
21.9
15.6
15.6
6.3
t
r
e
a
t
m
e
n
t
 
a
n
d
 
o
u
t
c
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m
e
surgery of UUTT
radical
conservative
25
7
78.1
21.9
patient outcome
live
death (tumor /other)
26
6 (6/1)
81.3
18.7
follow-up time (month) 78+-46 Medin 60
* significant for patient OS, 
Abbr. BEN – Balkan nephropathy, UUTT – upper urinary tract carcinoma, OS – overall survival, HD – hemodialysisTUNEL, p53, Erbb2+ UroThELiaL TUmor 645
Table 2. Predictors of poor OS risk for UUTT associated with BEN: bilateral successive UUTT and triple positive [p53+, TUNEL>0.36% 
+cells in stage over 1]
Multivariate Cox-regression OS 
analysis
Exp (B) 95% CI p
Bilateral successive UUTT 4.15 1.10-15.61 0.035
s>1; TUNEL>0.36%; p53+ 7.07 1.03-48.32 0.046
Fig. 1. Kaplan Meier analysis of upper urinary tract epithelial 
carcinoma  by  tumor  bilateral  appearance  (log  rank  F=11.55; 
p=0.0031).
Fig. 3. Kaplan Meier analysis of upper urinary tract epithelial 
carcinoma by double marker p53+ (>10%+ cells) and c-ErbB2+ 
cells >0 (log rank F=12.85;p=0.0050).
Fig. 2. Kaplan Meier analysis of upper urinary tract epithelial 
carcinoma by double marker TUNEL+ (>0.4%+ cells) and c-
ErbB2+ (Log Rank F=8.90; p=0.0307).
Fig. 4. Kaplan Meier analysis of upper urinary tract epithelial 
carcinoma  by  triple  marker  >pT1/TUNEL+/p53+  (log  rank 
F=5.23; p=0.0222).646 MARINA SAVIN ET AL.
survival, although the stage of local invasion in com-
bination with single molecular marker, either p53 
or the apoptosis index, may not predict the risk of 
patient OS. Finally, cross-relations of the last three 
markers,  stage>1,  high  apoptosis  index  and  p53+ 
overexpression may define more efficiently the risk 
of poor OS. An apoptosis index >0.4% and p53+ tu-
mor status in pT>1 are linked with poor survival in 
two survival tests (Cox regression analysis; (p=0.045) 
and log rank test (p=0.0222) (Figs. 4, 5)). The same 
risk of 6.35 times (95%CI=1.04-38.65) of poor OS 
was  calculated  by  decreasing  the  apoptosis  index 
from [>0.40%] to [>0.36%]; the last was the putative 
cut-off for pT1 into pT2 stage of local expansion that 
suggests the possibility of an early worse prognosis 
for BEN-related tumors that are restricted to urothe-
lial mucosa [stage>1, apoptosis index>0.36, p53+]. A 
triple-positive marker was associated with the risk of 
poor outcome, particularly in patients with bilateral 
successive  UUTT,  by  multivariate  Cox  regression 
analysis (Table 2).
DISCUSSION
Balkan  endemic  nephropathy  frequently  appears 
in several villages of endemic areas in Serbia, with 
the same incidence as 50 years ago when Petkovic 
discovered UUTT associated with BEN (Petkovic, 
1975; Jankovic et al., 2013). Recurring and/or new 
urothelial tumor appearance is common and a large 
portion of patients undergo hemodialysis for several 
years due to the slow progression of BEN after radi-
cal surgical treatment of UUTT. Our follow-up time 
was prolonged in order to examine the usefulness of 
tumor tissue-based molecular biomarkers in OS pre-
diction. Six out of 32 patients died (mortality rate of 
18.7%) due to recurring disease or invasion from 12-
216 months. The great OS median time of 60 months 
after the operation illustrated the slow progression of 
BEN and confirmed a long induction time for new 
or recurring urothelial tumor and the slow growth of 
multiple tumors (Petronic, 2000). A bias for an im-
proved outcome after conservative vs radical kidney 
operation was not observed; however, all mortal out-
comes were reported after radical surgical treatment; 
sepsis after surgery was not common (Savin, 2013). 
In fact, tumor bilateral growth was the only urologic 
factor pointing to poor OS, probably because of sev-
eral additional unfavorable conditions, including the 
need for regular hemodialysis. 
Fig. 5. TUNEL+ cells (>0.4%) in UUTT of grade 3 and stage pT3 developed in a patient with Balkan nephropathy.TUNEL, p53, Erbb2+ UroThELiaL TUmor 647
Krasteva et al. (2006) screened 90 Bulgarian BEN 
patients for p53 gene mutations, establishing muta-
tions in the patients. The investigations of Grollman 
et al. (2007) and Jelakovic et al. (2012) revealed that 
aristolochic  acid  is  genotoxic,  inducing  a  charac-
teristic p53 mutational profile of UUTT associated 
with BEN in rural households in Croatia. It has been 
suggested that exposure to aristolochic acids could 
result from the consumption of wheat contaminated 
with seeds of Aristolochia clematitis (Hranjec et al., 
2005). These investigations provided additional sup-
port for the toxic etiology of UUTT in BEN regions, 
and that BEN-associated tumors possess specific bio-
logical features. Analysis of UUTT associated with 
chronic aristolochic acid intoxication in Taiwan has 
ascertained a dose-dependent relationship between 
cumulative aristolochic acid exposure and end-stage 
renal disease or UUTT development (Wu and Wang, 
2013), and increased risk of new urothelial malig-
nancies (Lemy et al., 2008).
Our study suggests that the most reliable predic-
tor for OS was the combination of two positive bi-
omarkers, the apoptosis index >0.36% and p53>10% 
cells that provided for 6.35-fold higher risk for poor 
OS after surgery (pT stage greater than 1). This is an 
evidence for p53 overexpression/mutation and apop-
tosis deregulation in tumor invasiveness under en-
vironmental toxin action. This is the first report on 
the linkage of tissue-based molecular biomarker to 
mortality rate for BEN-associated urothelial carcino-
ma, suggesting that mutagenic and cytotoxic effects 
play a role in the development of UUTT associated 
with BEN. We have previously discovered early de-
regulation of apoptosis in BEN-related UUTT that 
may  have  even  two  times  lower  apoptosis  cut-off  
value for progression of cell atypia than for tumors 
diagnosed outside of the endemic regions (0.37 vs 
0.61% of TUNEL+ cells). A delayed increase in ap-
optosis is apparent in high grade UUTT associated 
with BEN (Petronic and Savin, 2001; Savin and Pet-
ronic, 2002). Jankovic Velickovic at al. (2011) dem-
onstrated decreased pro-apoptotic activity in tumors 
arising in endemic regions. The authors discovered 
a connection between Bax overexpression with the 
stage of tumor invasion. Our results indicate that an 
apoptosis index greater than 0.36% of TUNEL+ cells 
could define tumor invasiveness besides c-ErbB2+ or 
increased grade of cell atypia. The prognostic value 
of tumor apoptosis was not restricted to BEN-relat-
ed tumors. Jeong et al. (2009) displayed that T stage 
and early deregulation of apoptosis were associated 
with survival in UUTT of unspecified etiology. They 
applied the TdT-mediated DUTP nick-end labeling 
method to obtain the apoptotic index. 
Tumor-based molecular investigation of UUTT 
from the South Morava River basin in Serbia revealed 
p53  protein  overexpression  (>10%  cells)  in  60% 
cases, as a specific marker for BEN-related UUTT 
(Jankovic Velickovic et al., 2009). p53+ overexpres-
sion was displayed by only 37.5% tumors. Results of 
meta-analysis suggest that p53+ might be a prognos-
tic factor of OS for patients with UUTT. The analysis 
included 514 UUTT patients from the general popu-
lation (Ku et al., 2013). We found that neither p53+ 
nor the apoptosis index can predict OS in UUTT as-
sociated with BEN, however a double marker [p53+, 
c-ErbB2+]  or  [TUNEL+,  c-ErbB2+]  pointed  to  a 
worse OS in the Kaplan Meier analysis. The c-ErbB2 
mutation is regarded as an important risk marker 
of tumor progression. We concluded that c-ErbB2+ 
enhanced the instability of tumors with suppressor 
protein p53 deregulation, the same as cErbB2+ acts 
together with deregulated apoptosis (over 0.40% of 
TUNEL+ cells). The finding points to a specific mu-
tation of c-ErbB2, similarly as documented for p53. 
Chae et al. (2012) performed a molecular epidemio-
logic study of UUTT cases in Taiwan where Aristolo-
chia herbal remedies have been used extensively for 
many years. They found several specific mutational 
signatures dominated by otherwise rare A:T to T:A 
transversions, mainly in p53 (identical to that ob-
served in UUTT associated with BEN), and HRAS 
and FGFR3 gene. Deoxyadenosine (dA)-AL adducts 
were detected in the majority (10/13, 76.9%) of pa-
tients carrying A→T transversions. Prominent p53 
mutational  hotspots  include  the  adenine  bases  of 
5′AG (acceptor) splice sites located almost exclusive-
ly on the non-transcribed strand. A:T to T:A muta-
tions were also detected at activating positions in the 
FGFR3 and HRAS oncogenes. The EGFR family is a 648 MARINA SAVIN ET AL.
major class of receptor tyrosine kinase (RTK) pro-
to-oncogenes, including EGFR, ErbB2 (Her2-neu), 
EGFR3 and EGFR4, whose homo- and heterodimers 
are activated by EGF (Lee et al., 1989). The amplifica-
tion of c-ErbB2 and overexpression of its product in 
urothelial carcinoma has been associated with tumor 
grade, stage and patient outcome (Tsai et al., 2005). 
These authors, using multivariate analyses, suggested 
that tumor stage and c-ErbB2 expression were inde-
pendent predictors of disease progression and OS. 
Investigations included 94 cases with UUTT in Tai-
wan that consumed traditional remedies with aris-
tolochic acid. We presume that c-ErbB2/EGFR3 het-
erodimers are dysfunctional, especially in cErbB2+ 
(overexpression) UUTT from BEN regions, and that 
this probably results in deregulation of intracellular 
signaling.  Additionally,  the  c-ErbB2  gene  may  be 
specifically mutated (Petronic and Savin, 2002), the 
same as p53 and EGFR3 genes. These patients were 
prone to recurring or new disease, also a characteris-
tic of UUTT associated with BEN.
Our investigation supports the concept that spe-
cific gene deregulation is responsible for specific fea-
tures of BEN-related tumors. Molecular prognostic 
tumor mapping of risks to patient OS needs to in-
clude several markers, including p53, c-ErbB2 and 
apoptosis deregulation (Savin et al., 2001).
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